• Arena Pharmaceuticals Reports Positive Results for Olorinab americanpharmaceuticalreview
    September 27, 2018
    Arena Pharmaceuticals announced positive topline results from its Phase 2a trial of olorinab, an investigational, peripherally restricted, highly selective, full agonist of the cannabinoid receptor 2 (CB2) in development for the treatment of gastrointesti
PharmaSources Customer Service